Table of Contents Author Guidelines Submit a Manuscript
Stroke Research and Treatment
Volume 2014, Article ID 358640, 4 pages
Research Article

Bolus-Infusion Delays of Alteplase during Thrombolysis in Acute Ischaemic Stroke and Functional Outcome at 3 Months

1Acute Stroke Service, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK
2School of Social and Community Medicine, University of Bristol, Bristol BS8 2PS, UK
3Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne NE2 4HH, UK

Received 6 February 2014; Revised 7 April 2014; Accepted 7 April 2014; Published 30 April 2014

Academic Editor: David S. Liebeskind

Copyright © 2014 Paul Acheampong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. R. Lees, E. Bluhmki, R. von Kummer et al., “Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials,” The Lancet, vol. 375, no. 9727, pp. 1695–1703, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Tanswell, E. Seifried, P. C. A. F. Su, W. Feuerer, and D. C. Rijken, “Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects,” Clinical Pharmacology and Therapeutics, vol. 46, no. 2, pp. 155–162, 1989. View at Google Scholar · View at Scopus
  3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, “Tissue plasminogen activator for acute ischemic stroke,” The New England Journal of Medicine, vol. 333, pp. 1581–1571, 1995. View at Google Scholar
  4. P. Acheampong and G. A. Ford, “Pharmacokinetics of alteplase in the treatment of ischaemic stroke,” Expert Opinion on Drug Metabolism and Toxicology, vol. 8, no. 2, pp. 271–281, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Smith, Y. Al-Nuaimi, J. Wainwright et al., “The influence of bolus to infusion delays on plasma Tissue Plasminogen Activator levels,” International Journal of Stroke, 2012. View at Publisher · View at Google Scholar
  6. X. Huang and K. W. Muir, “Does alteplase bolus infusion delay affect outcome?” International Journal of Stroke, vol. 7S2, article 13, 2012. View at Google Scholar
  7. E. Seifried, P. Tanswell, D. Ellbruck, W. Haerer, and A. Schmidt, “Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction,” Thrombosis and Haemostasis, vol. 61, no. 3, pp. 497–501, 1989. View at Google Scholar · View at Scopus
  8. E. C. Haley Jr., D. E. Levy, T. G. Brott et al., “Urgent therapy for stroke: part II. Pilot study of tissue plasminogen activator administered 91–180 minutes from onset,” Stroke, vol. 23, no. 5, pp. 641–645, 1992. View at Google Scholar · View at Scopus